Valuation: Beta Bionics, Inc.

Market Cap 793M 687M 643M 587M 1.1B 75.61B 1.12B 7.54B 2.95B 37.84B 2.98B 2.91B 126B P/E 2026 *
-8.23x
P/E 2027 * -8.18x
Enterprise Value 659M 571M 535M 488M 918M 62.86B 933M 6.27B 2.46B 31.46B 2.47B 2.42B 105B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 4x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day+7.44%
1 week+20.93%
Current month+37.33%
1 month+3.46%
3 months+78.88%
6 months+24.79%
Current year-42.17%
1 week 13.62
Extreme 13.615
17.64
1 month 12.73
Extreme 12.73
18.2
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
6/24/26 A Sell

Executive/Senior Manager

-1,258 0.0028%
2/27/26 A Sell

Executive/Senior Manager

59,813 0.1359%
2/27/26 A Free

Chief Executive Officer

287,944 0.6541%
Change 5-day change 1-year change 3-year change Capi.($)
+7.44%+20.93%+23.22% - 793M
+0.89%+7.13%+30.84%+11.26% 224B
-0.92%+6.50%+3.84%-18.78% 146B
+2.00%+8.95%-14.97%+31.77% 142B
+1.45%+4.28%-50.18%+0.31% 74.19B
+1.77%+4.53%+19.83%+17.94% 53.99B
-0.68%+0.46%-14.80%-16.32% 50.85B
+0.52%+7.39%+30.98%+17.84% 42.22B
+0.78%+4.78%+48.59%+42.29% 40.75B
-0.26%+3.54%-0.34%+1.62% 32.86B
Average +1.16%+6.86%+7.70%+9.77% 80.69B
Weighted average by Cap. +0.46%+6.25%+6.48%+8.65%

Financials

2026 *2027 *
Net sales 134M 116M 109M 99.05M 186M 12.76B 190M 1.27B 499M 6.39B 502M 491M 21.31B 180M 156M 146M 133M 250M 17.15B 255M 1.71B 670M 8.58B 675M 660M 28.63B
Net income -95.11M -82.42M -77.16M -70.4M -132M -9.07B -135M -905M -354M -4.54B -357M -349M -15.15B -96.44M -83.58M -78.24M -71.39M -134M -9.2B -137M -917M -359M -4.6B -362M -354M -15.36B
Net Debt -134M -116M -108M -98.98M -186M -12.75B -189M -1.27B -498M -6.38B -502M -491M -21.3B -73.32M -63.54M -59.48M -54.27M -102M -6.99B -104M -697M -273M -3.5B -275M -269M -11.68B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
11/08/26 $17.62 +7.44% 613,918
10/08/26 $16.40 +3.14% 1,316,058
07/08/26 $15.90 +12.69% 1,274,256
06/08/26 $14.11 +1.44% 590,198
05/08/26 $13.91 -4.53% 897,075
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
17.62USD
Average target price
20.31USD
Spread / Average Target
+15.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock